These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35962999)

  • 1. LONG-TERM EFFECTS OF ANTI-VEGF MONOTHERAPY FOR RETINOPATHY OF PREMATURITY ON THE RETINAL AND REFRACTIVE DEVELOPMENT OF EYE.
    Sukgen EA; Atalay HT; Özdek Ş
    Retina; 2022 Nov; 42(11):2194-2202. PubMed ID: 35962999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
    Sankar MJ; Sankar J; Chandra P
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD009734. PubMed ID: 29308602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-vascular Endothelial Growth Factor Treatment of Retinopathy of Prematurity: Efficacy, Safety, and Anatomical Outcomes.
    Kang HG; Choi EY; Byeon SH; Kim SS; Koh HJ; Lee SC; Kim M
    Korean J Ophthalmol; 2018 Dec; 32(6):451-458. PubMed ID: 30549468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reactivation of retinopathy of prematurity after ranibizumab treatment.
    Wong RK; Hubschman S; Tsui I
    Retina; 2015 Apr; 35(4):675-80. PubMed ID: 25768252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retinal Detachment after Treatment of Retinopathy of Prematurity with Laser versus Intravitreal Anti-Vascular Endothelial Growth Factor.
    Barry GP; Yu Y; Ying GS; Tomlinson LA; Lajoie J; Fisher M; Binenbaum G;
    Ophthalmology; 2021 Aug; 128(8):1188-1196. PubMed ID: 33387554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined Vitrectomy and Anti-VEGF Treatment for Stage 4 Retinopathy of Prematurity With Extensive Neovascular Proliferation.
    Chandra P; Kumawat D; Agarwal D; Chawla R
    J Pediatr Ophthalmol Strabismus; 2020 Jan; 57(1):61-66. PubMed ID: 31972043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
    Sankar MJ; Sankar J; Mehta M; Bhat V; Srinivasan R
    Cochrane Database Syst Rev; 2016; 2():CD009734. PubMed ID: 26932750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of bevacizumab, ranibizumab and aflibercept in retinopathy of prematurity treatment.
    Süren E; Özkaya D; Çetinkaya E; Kalaycı M; Yiğit K; Kücük MF; Erol MK
    Int Ophthalmol; 2022 Jun; 42(6):1905-1913. PubMed ID: 35094229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison in Retreatments between Bevacizumab and Ranibizumab Intravitreal Injections for Retinopathy of Prematurity: A Multicenter Study.
    Patel NA; Acaba-Berrocal LA; Hoyek S; Fan KC; Martinez-Castellanos MA; Baumal CR; Harper CA; Berrocal AM;
    Ophthalmology; 2023 Apr; 130(4):373-378. PubMed ID: 36396121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity.
    Sukgen EA; Koçluk Y
    Graefes Arch Clin Exp Ophthalmol; 2019 Jan; 257(1):49-55. PubMed ID: 30397793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Fluorescein Angiography Findings in Stage 3 Retinopathy of Prematurity in Zone II Treated With or Without Anti-VEGF.
    Vural A; Demirayak B; Ozbas M; Onur IU; Celik G
    Eur J Ophthalmol; 2022 Nov; 32(6):3281-3288. PubMed ID: 35191353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal Bevacizumab for Zone II Retinopathy of Prematurity.
    Larrañaga-Fragoso P; Peralta J; Bravo-Ljubetic L; Pastora N; Abelairas-Gómez J
    J Pediatr Ophthalmol Strabismus; 2016 Nov; 53(6):375-382. PubMed ID: 27537247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural and refractive outcomes of intravitreal ranibizumab followed by laser photocoagulation for type 1 retinopathy of prematurity.
    Hoppe C; Holt DG; Arnold BF; Thinda S; Padmanabhan SP; Oatts JT
    J AAPOS; 2022 Dec; 26(6):305.e1-305.e6. PubMed ID: 36265750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity.
    Tahija SG; Hersetyati R; Lam GC; Kusaka S; McMenamin PG
    Br J Ophthalmol; 2014 Apr; 98(4):507-12. PubMed ID: 24403566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes of type 1 retinopathy of prematurity following monotherapy with bevacizumab: a Canadian experience.
    Isaac M; Mireskandari K; Fallaha N; Ospina LH; Javidi E; Chorfi S; Superstein R; Hamel P; Tehrani NN
    Can J Ophthalmol; 2023 Dec; 58(6):553-558. PubMed ID: 35940211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiographic findings in cases with a history of severe retinopathy of prematurity treated with anti-VEGFs: Follow-up to age 6 years.
    Celiker H; Sahin O
    Int Ophthalmol; 2022 Apr; 42(4):1317-1337. PubMed ID: 34729633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab.
    Chen SN; Lian I; Hwang YC; Chen YH; Chang YC; Lee KH; Chuang CC; Wu WC
    Retina; 2015 Apr; 35(4):667-74. PubMed ID: 25462435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of optical coherence tomography biomarkers to differentiate favourable and unfavourable responders to intravitreal anti-vascular endothelial growth factor treatment in retinopathy of prematurity.
    Belenje A; Reddy RU; Parmeswarappa DC; Padhi TR; Subbarao B; Jalali S
    Eye (Lond); 2024 Apr; 38(6):1097-1103. PubMed ID: 37968517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Intravitreal Bevacizumab, Intravitreal Ranibizumab and Laser Photocoagulation for Treatment of Type 1 Retinopathy of Prematurity in Turkish Preterm Children.
    Kabataş EU; Kurtul BE; Altıaylık Özer P; Kabataş N
    Curr Eye Res; 2017 Jul; 42(7):1054-1058. PubMed ID: 28128986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FLUORESCEIN ANGIOGRAPHIC EVALUATION OF PERIPHERAL RETINAL VASCULATURE AFTER PRIMARY INTRAVITREAL RANIBIZUMAB FOR RETINOPATHY OF PREMATURITY.
    Harper CA; Wright LM; Young RC; Read SP; Chang EY
    Retina; 2019 Apr; 39(4):700-705. PubMed ID: 29300248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.